Table 1.
Basic characteristics of the included patients.
| Variables | Overall | PTBS group (n = 71) | PTBS + 125I group (n = 113) | p value |
|---|---|---|---|---|
| Gender (male/female) | 118/66 | 43/28 | 75/38 | 0.424 |
| Age (y) | 68.9 ± 12.3 | 68.8 ± 14.1 | 68.9 ± 11.0 | 0.819 |
| Location (HCCA/DCCA) | 117/67 | 44/27 | 73/40 | 0.718 |
| CA19-9 (ng/ml) | 650.0 (0.6–2068) | 886 (1.1–1967) | 509.2 (0.6–2068) | 0.358 |
| CEA (ng/ml) | 4.4 (0.9–490.5) | 4.4 (1.0–490.5) | 4.4 (0.9–490.5) | 0.510 |
| ALT (U/L) | 131 (18–542) | 106 (18–542) | 149 (22–513) | 0.001 |
| AST (U/L) | 134 (19–793) | 98 (19–793) | 158 (28–541) | <0.001 |
| ALP (U/L) | 487 (39–2556) | 404 (102–1990) | 553 (39–2556) | 0.013 |
| GGT (U/L) | 484(4.1–2528) | 406(47–1837) | 534 (4.1–2528) | 0.047 |
| TBIL (µmol/L) | 224.7 (5.8–706.2) | 158 (5.8–551.5) | 249.7 (14.1–706.2) | 0.003 |
| DBIL (µmol/L) | 179.3 (3.0–649.0) | 150 (3–424) | 201.4 (5–649) | 0.006 |
| ALB (g/L) | 34.3 (23.6–45.3) | 34.6 (25.1–43.6) | 34.2 (23.6–45.3) | 0.669 |
| PT-INR | 1.03 (0.63–16.5) | 1.1 (0.6–1.6) | 1.0 (0.7–16.5) | 0.234 |
| NC (109/L) | 4.5 (1.6–35.6) | 4.8 (1.7–34.8) | 4.3 (1.6–35.6) | 0.236 |
| LC (109/L) | 1.3 (0.3–4.2) | 1.2 (0.3–2.8) | 1.4(0.4–4.2) | 0.152 |
| PLT (109/L) | 241 (30–644) | 252 (30–644) | 237 (54–533) | 0.817 |
| CRP (mg/L) | 16.4 (0.6–270.0) | 16.3 (1.5–270.0) | 16.4 (0.6–205.6) | 0.332 |
| The length of stay (d) | 14 (3–47) | 13 (3–47) | 15 (4–34) | 0.058 |
| Hospital costs (CNY) | 34,368 (5,533–64,267) | 28,821 (14,442–64,267) | 36,631 (5,533–61,928) | <0.001 |
| Survival time (m) | 9 (1–30) | 7 (1–13) | 12 (1–30) | <0.001 |
PTBS percutaneous transhepatic biliary stenting, HCCA hilar cholangiocarcinoma, DCCA distal cholangiocarcinoma, CA19-9 carbohydrate antigen 19-9, CEA carcino-embryonic antigen, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT gamma-glutamyl transpeptidase, TBIL total bilirubin, DBIL direct bilirubin, ALB albumin, PT-INR prothrombin time-international normalized ratio, NC neutrophil count, LC lymphocyte count, PLT platelet count, CRP c-reactive protein.